Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 106Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Combivir

02 5Dovato

03 2Epzicom/Kivexa

04 5Triumeq

05 5Zeffix

PharmaCompass

01

Brand Name : Triumeq

Lamivudine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Triumeq

arrow
Antibody Engineering
Not Confirmed

Lamivudine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 3,197

2019 Revenue in Millions : 3,534

Growth (%) : -10

blank

02

Brand Name : Epzicom/Kivexa

Lamivudine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Epzicom/Kivexa

arrow
Antibody Engineering
Not Confirmed

Lamivudine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 43

2019 Revenue in Millions : 104

Growth (%) : -59

blank

03

Brand Name : Dovato

Lamivudine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Dovato

arrow
Antibody Engineering
Not Confirmed

Lamivudine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 518

2019 Revenue in Millions : 78

Growth (%) : 568

blank

04

Brand Name : Dovato

Lamivudine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Dovato

arrow
Antibody Engineering
Not Confirmed

Lamivudine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 1,065

2020 Revenue in Millions : 512

Growth (%) : 110

blank

05

Brand Name : Triumeq

Lamivudine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Triumeq

arrow
Antibody Engineering
Not Confirmed

Lamivudine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 2,547

2020 Revenue in Millions : 3,159

Growth (%) : -18

blank

06

Brand Name : Triumeq

Lamivudine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Triumeq

arrow
Antibody Engineering
Not Confirmed

Lamivudine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2022 Revenue in Millions : 2,218

2021 Revenue in Millions : 2,547

Growth (%) : -13

blank

07

Brand Name : Dovato

Lamivudine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Dovato

arrow
Antibody Engineering
Not Confirmed

Lamivudine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2022 Revenue in Millions : 1,695

2021 Revenue in Millions : 1,065

Growth (%) : 59

blank

08

Brand Name : Triumeq

Lamivudine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Triumeq

arrow
Antibody Engineering
Not Confirmed

Lamivudine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2023 Revenue in Millions : 1,664

2022 Revenue in Millions : 2,218

Growth (%) : -14

blank

09

Brand Name : Dovato

Lamivudine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Dovato

arrow
Antibody Engineering
Not Confirmed

Lamivudine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2023 Revenue in Millions : 1,963

2022 Revenue in Millions : 1,695

Growth (%) : 32

blank

10

Brand Name : Zeffix

Lamivudine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Zeffix

arrow
Antibody Engineering
Not Confirmed

Lamivudine

Main Therapeutic Indication : Infectious Diseases (HIV, Hepatitis...

Currency : USD

2015 Revenue in Millions : 236

2014 Revenue in Millions : 190

Growth (%) : -19%

blank